Targeting HER2 by Combination Therapies

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE. December 15, 2017 ARTICLE CITATION DOI: 10.1200/JCO.2017.77.1899 Journal of Clinical Oncology - published online before print January 30, 2018 PMID: 29381433 Targeting HER2 by Combination Therapies Ana Ruiz-SaenzxAna Ruiz-SaenzSearch for articles by this author and Mark M. MoasserxMark M. MoasserSearch for articles by this author Show More Ana Ruiz-Saenz, University of California at San Francisco, San Francisco, CA; and Mark M. Moasser, University of California at San Francisco, San Francisco, CA https://doi.org/10.1200/JCO.2017.77.1899 First Page Full Text PDF Figures and Tables © 2018 by American Society of Clinical Oncology Companion Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE